#Daiichi-Sankyo

2 stories

Regulatory September 17, 2026 · View digest

NICE Final Draft Guidance Recommends Enhertu for HER2-Low Advanced Breast Cancer, Reversing an Earlier Rejection

NICE published final draft guidance on Thursday, September 17, 2026 recommending Enhertu (trastuzumab deruxtecan, from Daiichi Sankyo and AstraZeneca) for adults with HER2-low advanced or metastatic breast cancer whose disease has progressed after treatment, a group NICE estimated at about 1,000 people. NICE had previously rejected the drug for this use on cost-effectiveness grounds. It said the reversal followed an agreed commercial solution, the higher cost-effectiveness thresholds it began using in April 2026, and a new method for assessing quality of life published on August 27, 2026. The guidance is open to appeal until 5pm on October 7, 2026.

Industry April 28, 2026 · View digest

Daiichi Sankyo + Meddenovo Mexa AI Collaboration: De Novo Cyclic Peptide Design Featured at Boston Summit

Daiichi Sankyo's collaboration with Meddenovo's AI-powered Mexa technology — for de novo design of cyclic peptides — is among the highlighted partnerships at the Boston peptide summit. The deal positions Daiichi to leverage Meddenovo's machine-learning platform for peptide candidates beyond the company's traditional small-molecule oncology focus. Cyclic peptide AI design is one of the fastest-moving subcategories in peptide drug discovery, with Circle Pharma, Bicycle Therapeutics, and Unnatural Products all pursuing distinct platform architectures.